Literature DB >> 33803295

Does COVID-19 Vaccination Warrant the Classical Principle "ofelein i mi vlaptin"?

Michael Doulberis1, Apostolis Papaefthymiou1,2, Georgios Kotronis3, Dimitra Gialamprinou4, Elpidoforos S Soteriades5,6, Anthony Kyriakopoulos7, Eleftherios Chatzimichael8, Kyriaki Kafafyllidou9, Christos Liatsos10, Ioannis Chatzistefanou11, Paul Anagnostis12, Vitalii Semenin13, Smaragda Ntona14, Ioanna Gkolia15, Dimitrios David Papazoglou16, Nikolaos Tsinonis17, Spyros Papamichos1, Hristos Kirbas18, Petros Zikos19, Dionisios Niafas20, Jannis Kountouras1.   

Abstract

The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic warrants an imperative necessity for effective and safe vaccination, to restrain Coronavirus disease 2019 (COVID-19) including transmissibility, morbidity, and mortality. In this regard, intensive medical and biological research leading to the development of an arsenal of vaccines, albeit incomplete preconditioned evaluation, due to emergency. The subsequent scientific gap raises some concerns in the medical community and the general public. More specifically, the accelerated vaccine development downgraded the value of necessary pre-clinical studies to elicit medium- and long-term beneficial or harmful consequences. Previous experience and pathophysiological background of coronaviruses' infections and vaccine technologies, combined with the global vaccines' application, underlined the obligation of a cautious and qualitative approach, to illuminate potential vaccination-related adverse events. Moreover, the high SARS-CoV-2 mutation potential and the already aggregated genetical alterations provoke a rational vagueness and uncertainty concerning vaccines' efficacy against dominant strains and the respective clinical immunity. This review critically summarizes existing evidence and queries regarding SARS-CoV-2 vaccines, to motivate scientists' and clinicians' interest for an optimal, individualized, and holistic management of this unprecedented pandemic.

Entities:  

Keywords:  COVID-19; Hippocrates; Primum non nocere; SARS-COV-2; ofelein i mi vlaptin; vaccination; vaccine

Mesh:

Substances:

Year:  2021        PMID: 33803295      PMCID: PMC7999356          DOI: 10.3390/medicina57030253

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  130 in total

1.  The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.

Authors:  P Conti; Al Caraffa; C E Gallenga; S K Kritas; I Frydas; A Younes; P Di Emidio; G Tetè; F Pregliasco; G Ronconi
Journal:  J Biol Regul Homeost Agents       Date:  2021 Jan-Feb       Impact factor: 1.711

Review 2.  Prospects for a safe COVID-19 vaccine.

Authors:  Barton F Haynes; Lawrence Corey; Prabhavathi Fernandes; Peter B Gilbert; Peter J Hotez; Srinivas Rao; Michael R Santos; Hanneke Schuitemaker; Michael Watson; Ann Arvin
Journal:  Sci Transl Med       Date:  2020-10-19       Impact factor: 17.956

Review 3.  A Comparison of Plasmid DNA and mRNA as Vaccine Technologies.

Authors:  Margaret A Liu
Journal:  Vaccines (Basel)       Date:  2019-04-24

4.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

5.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Authors:  Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan
Journal:  Science       Date:  2020-02-19       Impact factor: 47.728

Review 6.  ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics.

Authors:  Judith A Hewitt; Cathleen Lutz; William C Florence; M Louise M Pitt; Srinivas Rao; Jay Rappaport; Nancy L Haigwood
Journal:  Cell Host Microbe       Date:  2020-10-01       Impact factor: 21.023

7.  Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.

Authors:  Yiska Weisblum; Fabian Schmidt; Fengwen Zhang; Justin DaSilva; Daniel Poston; Julio Cc Lorenzi; Frauke Muecksch; Magdalena Rutkowska; Hans-Heinrich Hoffmann; Eleftherios Michailidis; Christian Gaebler; Marianna Agudelo; Alice Cho; Zijun Wang; Anna Gazumyan; Melissa Cipolla; Larry Luchsinger; Christopher D Hillyer; Marina Caskey; Davide F Robbiani; Charles M Rice; Michel C Nussenzweig; Theodora Hatziioannou; Paul D Bieniasz
Journal:  Elife       Date:  2020-10-28       Impact factor: 8.140

8.  A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity.

Authors:  Priyanka Saha; Arup Kumar Banerjee; Prem Prakash Tripathi; Amit Kumar Srivastava; Upasana Ray
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

9.  Structure analysis of the receptor binding of 2019-nCoV.

Authors:  Yun Chen; Yao Guo; Yihang Pan; Zhizhuang Joe Zhao
Journal:  Biochem Biophys Res Commun       Date:  2020-02-17       Impact factor: 3.575

10.  SARS-CoV-2 genomic variations associated with mortality rate of COVID-19.

Authors:  Yujiro Toyoshima; Kensaku Nemoto; Saki Matsumoto; Yusuke Nakamura; Kazuma Kiyotani
Journal:  J Hum Genet       Date:  2020-07-22       Impact factor: 3.172

View more
  4 in total

Review 1.  Ofeleein i mi Vlaptin-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.

Authors:  Jannis Kountouras; Dimitra Gialamprinou; Georgios Kotronis; Apostolis Papaefthymiou; Eleftheria Economidou; Elpidoforos S Soteriades; Elisabeth Vardaka; Dimitrios Chatzopoulos; Maria Tzitiridou-Chatzopoulou; Dimitrios David Papazoglou; Michael Doulberis
Journal:  Medicina (Kaunas)       Date:  2022-02-17       Impact factor: 2.430

2.  PQQ Supplementation and SARS-CoV-2 Spike Protein-Induced Heart Inflammation.

Authors:  Alberto Boretti
Journal:  Nat Prod Commun       Date:  2022-03-08       Impact factor: 0.986

3.  Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs.

Authors:  Stephanie Seneff; Greg Nigh; Anthony M Kyriakopoulos; Peter A McCullough
Journal:  Food Chem Toxicol       Date:  2022-04-15       Impact factor: 5.572

Review 4.  Current Evidence in SARS-CoV-2 mRNA Vaccines and Post-Vaccination Adverse Reports: Knowns and Unknowns.

Authors:  Dimitra S Mouliou; Efthimios Dardiotis
Journal:  Diagnostics (Basel)       Date:  2022-06-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.